Jane E. Latz

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Alain C. Mita, Christopher J. Sweeney, Sharyn D. Baker et al. · Journal of Clinical Oncology · 2006 · 113 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

Xavier Pivot, Éric Raymond, Brigitte Laguerre et al. · British Journal of Cancer · 2001 · 88 citations · Full text

Medicine, Oncology, Pharmacology +13

Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

Jane E. Latz, Ajai K. Chaudhary, Atalanta Ghosh et al. · Cancer Chemotherapy and Pharmacology · 2005 · 84 citations

Medicine, Oncology, Pharmacokinetics +13

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

Jane E. Latz, Mats O. Karlsson, James J. Rusthoven et al. · Cancer Chemotherapy and Pharmacology · 2005 · 58 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Kazuhiko Nakagawa, Satoshi Kudoh, Kunihiko Matsui et al. · British Journal of Cancer · 2006 · 55 citations · Full text

Pharmacy, Oncology, Pharmacology +17